Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases

British Journal of Surgery

Volumn 98, Issue 11, 2011, Pages 1573-1580

  Deroose, J P ^a   Grunhagen D J ^a   Van Geel, A N ^a   De Wilt, J H W ^b   Eggermont, A M M ^a,c   Verhoef, C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AMPUTATION; ARTICLE; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; REGIONAL PERFUSION; SKIN TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; AMPUTATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80053574336     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.7621     Document Type: Article

References (32)

1. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA,. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996; 3: 446-452. (Pubitemid 126728589)
2. Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H, et al., Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0·8-2·0 mm. Cancer 2000; 89: 1495-1501.
3. Kandamany N, Mahaffey P,. Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases. Lasers Med Sci 2009; 24: 411-414.
4. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116. (Pubitemid 29318842)
5. Garbe C,. Perspectives of cytokine treatment in malignant skin tumors. Recent Results Cancer Res 1995; 139: 349-369.
6. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, et al., Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003; 21: 2883-2888. (Pubitemid 46621837)
7. Tan JK, Ho VC,. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993; 19: 985-990.
8. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M,. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 2008; 34: 232-240.
9. Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, et al., Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 2009; 20 (Suppl 6): vi22-vi29.
10. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al., Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
12. Eggermont AM,. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1996; 26: 335-349. (Pubitemid 126734884)
13. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, et al., Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16: 2906-2912.
14. Liénard D, Eggermont AM, Kroon BB, Schraffordt Koops H, Lejeune FJ,. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol 1998; 14: 202-209. (Pubitemid 28146511)
15. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ,. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
16. Eggermont AM, de Wilt JH, ten Hagen TL,. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4: 429-437. (Pubitemid 36833685)
17. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, et al., Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756-764.
18. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, et al., Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196-4201. (Pubitemid 46622299)
19. Grunhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM,. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004; 240: 939-947.
20. Rossi CR, Pasquali S, Mocellin S, Vecchiato A, Campana LG, Pilati P, et al., Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases. Ann Surg Oncol 2010; 17: 3000-3007.
21. Smith J,. Histopathology and Biological Behavior of Melanoma, Neoplasms of the Skin and Malignant melanomas. Year Book Medical Publishers: Chicago, 1976.
22. Vrouenraets BC, Klaase JM, Kroon BB, van Geel BN, Eggermont AM, Franklin HR,. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995; 130: 43-47.
23. World Health Organization (WHO). Handbook for Reporting Results of Cancer Treatment. WHO: Geneva, 1979.
24. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA,. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910. (Pubitemid 13147887)
25. Fraker DL, Alexander HR, Andrich M, Rosenberg SA,. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14: 479-489.
26. Knorr C, Meyer T, Janssen T, Goehl J, Hohenberger W,. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. Eur J Surg Oncol 2006; 32: 224-227. (Pubitemid 43257128)
27. Lejeune FJ, Liénard D, Leyvraz S, Mirimanoff RO,. Regional therapy of melanoma. Eur J Cancer 1993; 29A: 606-612. (Pubitemid 23036318)
28. Liénard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, et al., Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502. (Pubitemid 29494115)
29. Sanki A, Kam PC, Thompson JF,. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 2007; 245: 591-596. (Pubitemid 46555663)
30. Vaglini M, Belli F, Ammatuna M, Inglese MG, Manzi R, Prada A, et al., Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 1994; 73: 483-492. (Pubitemid 24030632)
31. Alexander HR Jr, Fraker DL, Bartlett DL, Libutti SK, Steinberg SM, Soriano P, et al., Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 2010; 28: 114-118.
32. Lejeune FJ, Eggermont AM,. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol 2007; 25: 1449-1450; author reply 1450-1441. (Pubitemid 46706902)